ProScience Research Group

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

  NCT07565428· Phase 3· Source

• Recruiting

  52-week Open Label Safety-Tolerability Study

  NCT07369154· Phase 3· Source

• Recruiting

  A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  NCT07424404· Phase 3· Source

• Recruiting

  Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

  NCT07363577· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  NCT07288567· Phase 3· Source

• Recruiting

  Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

  NCT07494305· Phase 2· Source

• Active, not recruiting

  An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

  NCT07217860· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  NCT07140913· Phase 3· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

  NCT07172516· Phase 3· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

  NCT06951711· Phase 3· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia5 recruiting
• Bipolar disorder4 recruiting
• Migraine2 recruiting
• Autism1 recruiting
• Depression1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Source

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Source

• Completed

  Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

  NCT06179108· Phase 2· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· Source

• Completed

  A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

  NCT05628103· Phase 3· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Source

• Recruiting

  Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

  NCT03817502· Phase 3· Source